Jim Hollingshead

Jim Hollingshead became president and CEO of Insulet Corporation in 2023, taking the helm of one of the fastest-growing medical device companies in the diabetes care space. Insulet's Omnipod is the world's only tubeless insulin delivery system — a small, wearable pod that replaces traditional insulin pumps connected by tubing. The Omnipod 5, launched in 2022-2023, was the first tubeless automated insulin delivery (AID) system to receive FDA clearance, integrating directly with Dexcom's continuous glucose monitor to automatically adjust insulin delivery. This combination of tubeless convenience and automated dosing has driven explosive adoption. Omnipod 5 dramatically simplifies diabetes management compared to traditional tubed pumps and multiple daily injection regimens, making it attractive to both Type 1 and increasingly Type 2 diabetes patients. International expansion — particularly in Europe, where Omnipod 5 is being rolled out across multiple countries — represents the company's largest growth opportunity, as international markets account for approximately half of revenue. Hollingshead's execution on the Omnipod 5 international rollout, customer acquisition rates, manufacturing scale-up, and gross margin expansion are the critical drivers of Insulet's stock price. The total addressable market for insulin delivery devices is estimated at over $20 billion globally, and Insulet is capturing share at an accelerating rate.